The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus

ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus

February 1, 2013 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The goal was to discover whether molecular signals associated with active lupus and no infection would differ from signals found in patients with both active disease flare and an infection.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
Explore This Issue
February 2013
Also By This Author
  • ACR/ARHP Annual Meeting 2012: Use a Combination of Tests, Patient History, and Physical Exam when Assessing Myopathies

Differences in upregulation of genes do suggest a gene expression gradient for disease activity in these acutely ill patients, Dr. Mackay said. Some highlights of the data are that significant upregulation of gene transcripts in interferon and plasma-cell modules differentiate subjects with a disease flare from those with an infection. Compared with stable lupus, acutely ill patients in both the flare and infection groups show an upregulation of genes in both the interferon and inflammation modules studied, she said. In the infection group, there was also an upregulation of neutrophil and myeloid modules.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Examining Joint Arthroplasty Rates

Christina Mertelsmann-Voss, MD, a researcher at the Hospital for Special Surgery in New York, examined increased joint arthroplasty rates among patients with SLE in the United States from 1991 to 2005.

The chronic inflammation associated with SLE can lead to arthritis and joint destruction, increasing the need for joint replacement, Dr. Mertelsmann-Voss said. SLE outcomes are improving due to advances in therapy, but do better treatments lead to less joint destruction and a decreased need for joint replacements, she asked?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

She and her colleagues looked at total and partial knee, hip, and shoulder replacement surgeries in SLE patients compared with patients who had no inflammatory or autoimmune disease. Looking at hospital code records, they excluded any people with a dual diagnosis of either rheumatoid arthritis (RA)/SLE or juvenile idiopathic arthritis/SLE that might also be causing joint destruction.

They identified 2,766,913 arthroplasties that included 4,253 surgeries involving lupus patients. In the noninflammatory group, rates almost doubled, while in the lupus group, they more than doubled. Rates of total knee replacements almost tripled, but the rate of total hip replacements decreased, she said.

The incidence of avascular necrosis in SLE patients decreased significantly, while the proportion of those with osteoarthritis significantly increased. In addition, the mean age at the time of arthroplasty for SLE patients rose from 47 to 57 years during the study. This change may be due to more-effective therapy preventing early, rapid joint destruction in SLE patients, she said. In addition, osteoarthritis (OA) as an indication increased dramatically, meaning that lupus patients, treated more effectively early on, are living longer and developing OA that requires surgery.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: comorbidities, Lupus, Research, SLE, TreatmentIssue: February 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • 2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)